Little Green Pharma Ltd.
AASX:LGP0.06
AUD
+0.00
(-6.15%)
ISIN
AU0000074924
Return %
Stock
S&P 500
1Y
-54.81
14.20
3Y
-60.65
81.12
5Y
-91.09
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Paul Long
- Full Time Employees
- 94
- Sector
- Process industries
- Industry
- Chemicals: major diversified
- Address
- PO Box 101 Shenton Park WA Australia 6913
- IPO Date
- Feb 20, 2020
- Website
- littlegreenpharma.com
- Similar Companies
- Business
- Little Green Pharma Ltd Little Green Pharma Ltd (ASX:LGP) is a vertically integrated medicinal cannabis company engaged in the cultivation, production, manufacturing, and distribution of pharmaceutical-grade cannabis products including dried flower medicines for vaporization and cannabis oils for oral ingestion; it also pursues research and development of new cannabis-based medicines and a psychedelics business encompassing psilocybin-assisted therapy clinical trials for refractory depression, mushroom cultivation facilities, and treatment clinics. Incorporated in 2016 and headquartered in West Perth, Australia, with manufacturing facilities in Australia and Denmark, the company supplies its LGP-branded portfolio across Australia and more than 12 international export markets, primarily in Europe, while supporting healthcare professionals through education, clinical trials, observational studies, and sustainable ESG practices via a dedicated Green Committee. Recent developments include the completion of its acquisition of Health House International Pty Ltd in early 2025, integrating a proven medicinal cannabis distribution business with approximately AUD7.5 million in annual revenue to enhance vertical integration and supply chain control; the issuance of its September 2025 quarterly activities report highlighting ongoing operational and financial updates; and continued expansion of production capacity at its Danish GMP facility for LGP-branded, white-label, and bulk flower products targeting global demand.